International Stem Cell Corporation Announces Second Patient with Parkinson’s Disease Treated in Phase I Clinical Trial
RUA GOLD Expands High-Grade Intercepts at Depth at Auld Creek: 5.9g/t AuEq over 9m and 48.3g/t AuEq over 1.25m
Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Blue Sky Uranium Increases and Closes 2nd and Final Tranche of the Oversubscribed Non-Brokered Private Placement
